Lixte Biotechnology Holdings, Inc. (LIXT)Healthcare | Biotechnology | Pasadena, United States | NasdaqCM
3.61 USD
+0.39
(12.112%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.62 +0.01 (0.277%) ⇧ (April 17, 2026, 6:10 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:54 p.m. EDT
LIXT appears to be a highly volatile stock with a negative earnings outlook and no dividend history. The recent price movements show some short-term momentum, but the overall trend is mixed, with a significant drop from the 52-week high. The stock has a low market cap and high debt-to-equity ratio, which raises concerns about its financial stability. The forecasting model suggests a negative price direction in the next 45 days, which indicates caution for short-term traders. Long-term investors should be wary due to the lack of consistent earnings and the company's financial risks. Overall, this stock is not recommended for either short-term or long-term investment at this time. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.065677 |
| AutoARIMA | 0.072950 |
| MSTL | 0.129808 |
| AutoETS | 0.136601 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.941 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.436 |
| Market Cap | 41,940,776 |
| Beta | 0.95 |
| Website | https://lixte.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5967741 |
| Address1 | 680 East Colorado Boulevard |
| Address2 | Suite 180 |
| All Time High | 110.4 |
| All Time Low | 0.64 |
| Ask | 2.98 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 36,800 |
| Average Daily Volume3 Month | 58,268 |
| Average Volume | 58,268 |
| Average Volume10Days | 36,800 |
| Beta | 0.947 |
| Bid | 3.36 |
| Bid Size | 1 |
| Book Value | 0.902 |
| City | Pasadena |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.61 |
| Current Ratio | 3.884 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.65 |
| Day Low | 3.23 |
| Debt To Equity | 9.436 |
| Display Name | Lixte Biotechnology |
| Dividend Date | 1,605,830,400 |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,510,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 40,897,344 |
| Eps Trailing Twelve Months | -1.26 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 631 982 5050 |
| Fifty Day Average | 2.9456 |
| Fifty Day Average Change | 0.66439986 |
| Fifty Day Average Change Percent | 0.22555672 |
| Fifty Two Week Change Percent | 159.67741 |
| Fifty Two Week High | 6.26 |
| Fifty Two Week High Change | -2.6500003 |
| Fifty Two Week High Change Percent | -0.4233227 |
| Fifty Two Week Low | 0.64 |
| Fifty Two Week Low Change | 2.9699998 |
| Fifty Two Week Low Change Percent | 4.640625 |
| Fifty Two Week Range | 0.64 - 6.26 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,193,319,000,000 |
| Float Shares | 11,606,907 |
| Free Cashflow | -1,278,703 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 3 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00456 |
| Held Percent Institutions | 0.07536 |
| Implied Shares Outstanding | 11,617,944 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,685,923,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. |
| Long Name | Lixte Biotechnology Holdings, Inc. |
| Market | us_market |
| Market Cap | 41,940,776 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_29181356 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -6,078,593 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 42,289,316 |
| Open | 3.28 |
| Operating Cashflow | -3,070,618 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 631 830 7092 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.27700806 |
| Post Market Price | 3.62 |
| Post Market Time | 1,776,463,824 |
| Previous Close | 3.22 |
| Price Hint | 4 |
| Price To Book | 4.0022173 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.831 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.39 |
| Regular Market Change Percent | 12.1118 |
| Regular Market Day High | 3.65 |
| Regular Market Day Low | 3.23 |
| Regular Market Day Range | 3.23 - 3.65 |
| Regular Market Open | 3.28 |
| Regular Market Previous Close | 3.22 |
| Regular Market Price | 3.61 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 29,676 |
| Return On Assets | -0.46001 |
| Return On Equity | -1.01953 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 11,617,944 |
| Shares Percent Shares Out | 0.0043 |
| Shares Short | 49,927 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 82,219 |
| Short Name | Lixte Biotechnology Holdings, I |
| Short Percent Of Float | 0.0044 |
| Short Ratio | 1.26 |
| Source Interval | 15 |
| State | CA |
| Symbol | LIXT |
| Total Cash | 5,106,872 |
| Total Cash Per Share | 0.44 |
| Total Debt | 1,034,377 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.8574 |
| Two Hundred Day Average Change | -0.24740005 |
| Two Hundred Day Average Change Percent | -0.064136475 |
| Type Disp | Equity |
| Volume | 29,676 |
| Website | https://lixte.com |
| Zip | 91,101 |